NCT04220203 2025-06-26Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast CancerSeagen Inc.Approved for marketing
NCT03424473 2020-02-25Expanded Access Use of Tucatinib for HER2+ Metastatic Breast CancerSeagen Inc.No longer available